India, May 9 -- Zealand Pharma A/S (ZLDPF) Friday announced that its collaboration and license agreement with Roche, first revealed on March 12, 2025, is now effective after fulfilling all closing and regulatory conditions.
CEO Adam Steensberg expressed enthusiasm about the partnership, describing it as a transformative move toward Zealand Pharma's goal of becoming a leading force in obesity treatment.
He emphasized Roche's alignment with the company's strategic vision and highlighted their shared commitment to advancing petrelintide for patients struggling with obesity.
ZLDPF is currently trading at $63.26 with no price change on the OTC Markets OTCPK.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Co...